Teva in the proposed divesture of its active-pharmaceutical ingredient (API) business
On January 31, 2024, Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or “TAPI”. TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide.
Wachtell, Lipton, Rosen & Katz is serving as legal counsel to Teva.